keyword
MENU ▼
Read by QxMD icon Read
search

Tardive

keyword
https://www.readbyqxmd.com/read/28716772/chewing-induced-facial-dystonia-a-rare-presentation-of-task-specific-dystonia
#1
Chandramohan Sharma, Banshi Lal Kumawat, Ankur Garg, Kaushik Kumar Rana
This case is an addition to scarce literature available for a rare condition, chewing-induced task-specific dystonia. The patient was a 63-year-old woman who presented with a 4-year history of progressive difficulty in eating food only during chewing associated with abnormal facial grimaces without any difficulty in drinking, swallowing, speaking or singing. Examination revealed dystonia of facial muscles every time she chewed but absent during drinking and speaking. As movements were consistent and reproducible with the specific task, other differential diagnosis like motor tics, psychogenic disorder, tardive dystonia and parkinsonism syndrome were excluded leading to a diagnosis of task-specific facial dystonia triggered by chewing...
July 17, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28708433/physical-health-outcomes-in-preschoolers-with-prior-authorization-for-antipsychotics
#2
Yu-Jung Wei, Xinyue Liu, Nikhil Rao, Marie McPherson, Mary Beth Jones, Regina Bussing, Almut G Winterstein
OBJECTIVE: To examine incidence of adverse health outcomes and associated factors among preschoolers (under age 6) who received antipsychotic treatment through the Florida Medicaid Prior Authorization (PA) program. METHODS: Using Florida's PA registry linked to the state's Medicaid claims data, we ascertained incident outcomes during PA-approved antipsychotic use between April 2008 and September 2015 (7.5 years). Six outcomes associated with use of antipsychotics included: diabetes, obesity, hyperlipidemia, hyperprolactinemia, cardiovascular disease (CVD) (including hypertension, ventricular arrhythmia, and other CVDs), and extrapyramidal symptoms (EPS) (including dystonia, akathisia, parkinsonism, and tardive dyskinesia)...
July 14, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28699794/valbenazine-for-the-treatment-of-tardive-dyskinesia
#3
Lauren C Seeberger, Robert A Hauser
Tardive dyskinesia (Td) is a hyperkinetic movement disorder that may result from treatment with antipsychotics or other dopamine receptor blocking agents. Underlying pathophysiology is incompletely understood but since the 1970s dopamine depleting agents have been used to reduce involuntary movements. The search for safe, effective treatments for Td is ongoing. Valbenazine, a novel VMAT2 inhibitor, has recently been FDA approved for treatment of Td. Areas Covered: An overview of Td, unmet medical needs and current treatment guidelines are presented...
July 12, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28696930/dramatic-improvement-of-tardive-dyskinesia-movements-by-inline-skating
#4
Sara Carvalho Barbosa Casagrande, Rubens Gisbert Cury, Andrea Cristina de Lima-Pardini, Daniel Boari Coelho, Carolina de Oliveira Souza, Maria Gabriela Dos Santos Ghilardi, Laura Silveira-Moriyama, Luis Augusto Teixeira, Egberto Reis Barbosa, Erich Talamoni Fonoff
No abstract text is available yet for this article.
July 11, 2017: Neurology
https://www.readbyqxmd.com/read/28668671/deutetrabenazine-for-treatment-of-involuntary-movements-in-patients-with-tardive-dyskinesia-aim-td-a-double-blind-randomised-placebo-controlled-phase-3-trial
#5
Karen E Anderson, David Stamler, Mat D Davis, Stewart A Factor, Robert A Hauser, Jouko Isojärvi, L Fredrik Jarskog, Joohi Jimenez-Shahed, Rajeev Kumar, Joseph P McEvoy, Stanislaw Ochudlo, William G Ondo, Hubert H Fernandez
BACKGROUND: Tardive dyskinesia results from exposure to dopamine receptor antagonists, such as typical and atypical antipsychotics. If clinically appropriate, clinicians often manage this disorder by lowering the dose of, or discontinuing, the causative drug. There is a significant unmet need for a treatment option that does not disrupt treatment regimens for underlying psychiatric illnesses. We aimed to assess the efficacy, safety, and tolerability of fixed doses of deutetrabenazine-a novel vesicular monoamine transporter-2 inhibitor-in patients with tardive dyskinesia...
June 28, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28668670/a-new-class-of-vmat-2-inhibitors-for-tardive-dyskinesia
#6
Christoph U Correll, Maren Carbon
No abstract text is available yet for this article.
June 28, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28658799/a-prospective-study-of-adverse-drug-reactions-in-patients-with-bipolar-disorder-in-psychiatry-outpatient-department-of-a-tertiary-care-hospital
#7
Aashal Shah, Preeti P Yadav, Mayur Chaudhari, Ankit Vataliya, N D Kantharia, Ritambhara Mehta
INTRODUCTION: Bipolar disorder is a chronic, debilitating psychiatric disorder. Mood stabilizers and atypical antipsychotics are first line drugs for bipolar disorder. They have significant adverse effects. AIM: The study was conducted with an aim to evaluate the pattern of occurrence of Adverse Drug Reactions (ADRs) in the patients with bipolar disorder and to assess their causality, severity and preventability. MATERIALS AND METHODS: A prospective and observational study - carried out in the psychiatry outpatient department of New Civil Hospital, Surat for 15 months...
May 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28653211/functional-psychogenic-stereotypies
#8
José Fidel Baizabal-Carvallo, Joseph Jankovic
Functional (psychogenic) movement disorders (FMDs) may present with a broad spectrum of phenomenology including stereotypic movements. We aimed to characterize the phenomenology of functional stereotypies and compare these features with those observed in 65 patients with tardive dyskinesia (TD). From a cohort of 184 patients with FMDs, we identified 19 (10.3%) with functional stereotypies (FS). There were 15 women and 4 men, with a mean age at onset of 38.6 ± 17.4 years. Among the patients with FS, there were 9 (47%) with orolingual dyskinesia/stereotypy, 9 (47%) with limb stereotypies, 6 (32%) with trunk stereotypies, and 2 (11%) with respiratory dyskinesia as part of orofacial-laryngeal-trunk stereotypy...
July 2017: Journal of Neurology
https://www.readbyqxmd.com/read/28647739/antipsychotic-induced-dopamine-supersensitivity-psychosis-pharmacology-criteria-and-therapy
#9
Guy Chouinard, Anne-Noël Samaha, Virginie-Anne Chouinard, Charles-Siegfried Peretti, Nobuhisa Kanahara, Masayuki Takase, Masaomi Iyo
The first-line treatment for psychotic disorders remains antipsychotic drugs with receptor antagonist properties at D2-like dopamine receptors. However, long-term administration of antipsychotics can upregulate D2 receptors and produce receptor supersensitivity manifested by behavioral supersensitivity to dopamine stimulation in animals, and movement disorders and supersensitivity psychosis (SP) in patients. Antipsychotic-induced SP was first described as the emergence of psychotic symptoms with tardive dyskinesia (TD) and a fall in prolactin levels following drug discontinuation...
2017: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/28647110/success-of-tardive-electroconvulsive-therapy-sessions-after-loxapine-induced-malignant-syndrome-in-the-context-of-very-poor-metabolisation
#10
Juliette Descoeur, Laurent Philibert, Kevin Chalard, Jérôme Attal, Pierre Petit, Kada Klouche, Mathieu Olivier
We report the success of tardive electroconvulsive therapy in a case of loxapine malignant syndrome with catatonia. Loxapine and its metabolites were measured in biological samples by liquid chromatography coupled to tandem mass spectrometry. Genes were studied by sequencing and quantitative polymerase chain reaction (PCR). Plasmatic drug concentrations showed a supratherapeutic concentration of loxapine with a very low 8-hydroxyloxapine/loxapine ratio (range from 0.32 to 0.66, normal value>2 for 100mg) and a very long elimination half-life of loxapine (half-life>140h, normal value from 1 to 4hours)...
May 29, 2017: Thérapie
https://www.readbyqxmd.com/read/28641484/protective-effect-of-hesperetin-against-haloperidol-induced-orofacial-dyskinesia-and-catalepsy-in-rats
#11
Dinesh Dhingra, Shikha Goswami, Nidhi Gahalain
OBJECTIVES: The present study was designed to evaluate the effect of hesperetin on haloperidol-induced orofacial dyskinesia and catalepsy in Wistar male albino rats. METHODS: Haloperidol (1 mg/kg, ip) was administered for 21 successive days to induce orofacial dyskinesia and catalepsy. Hesperetin (50 and 100 mg/kg, po) was administered 10 min prior to the injection of haloperidol for 21 successive days. Vacuous chewing movements (VCMs), tongue protrusions, catalepsy, and locomotor activity scores were recorded on 7th, 14th, and 22nd day of drug treatment...
June 22, 2017: Nutritional Neuroscience
https://www.readbyqxmd.com/read/28638290/medication-induced-tardive-dyskinesia-a-review-and-update
#12
REVIEW
Elyse M Cornett, Matthew Novitch, Alan David Kaye, Vijay Kata, Adam M Kaye
BACKGROUND: Tardive dyskinesia (TD) is a movement disorder that causes involuntary, repetitive body movements and is commonly seen in patients who are on long-term treatment with antipsychotic medications. However, several other classes of medications with different mechanisms are also associated with TD. METHODS: We conducted a PubMed search using keywords and combined word searches that involved medication-induced TD, as well as agents that are associated with causing or are used to treat medication-induced TD...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/28630641/amisulpride-withdrawal-dyskinesia-a-case-report
#13
Yu-Chi Lo, Ying-Chieh Peng
BACKGROUND: The effects of antipsychotic drug withdrawal have been inadequately studied. Case reports have described dyskinesia occurring in patients with several antipsychotics withdrawn, but studies on amisulpride withdrawal dyskinesia are lacking. CASE PRESENTATION: A 63-year-old man, who was diagnosed with schizophrenia at age 49, received amisulpride treatment since age 62. The dosage of amisulpride was reduced from 200 to 50 mg/day because of occurrence of akathisia during one admission...
2017: Annals of General Psychiatry
https://www.readbyqxmd.com/read/28583166/tardive-akathisia-related-to-the-anti-hypertensive-agent-sevikar-a-case-report
#14
Men-Ting Hsieh, Pao-Yen Lin, Chia-Jen Tsai, Chiung-Chih Chang, Yu Lee
BACKGROUND: Tardive akathisia (TA) is a subtype of tardive syndrome, and its etiology is still uncertain. Sevikar is an anti-hypertensive agent containing both amlodipine and olmesartan, and has never been reported to have an adverse reaction in patients with tardive syndrome. CASE PRESENTATION: A 57-year-old woman who took Sevikar for hypertension for 10 years developed TA one and a half years before receiving any psychiatric treatment. After switching from Sevikar to bisoprolol, she reported obvious improvement in her akathisia...
June 5, 2017: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28578484/valbenazine-first-global-approval
#15
REVIEW
Esther S Kim
Valbenazine (Ingrezza™) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by Neurocrine Biosciences for the treatment of various central nervous system disorders. Valbenazine has been approved in the USA for the treatment of adults with tardive dyskinesia (TD), is at various stages of development in other countries for TD and is in phase 2 development in the USA for Tourette syndrome. This article summarizes the milestones in the development of valbenazine leading to its first global approval in the USA for the treatment of adults with TD...
July 2017: Drugs
https://www.readbyqxmd.com/read/28577245/from-harmful-treatment-to-secondary-gain-adverse-event-reporting-in-dyspepsia-and-gastroparesis
#16
Klaus Bielefeldt
INTRODUCTION: Medical management of gastroparesis and functional dyspepsia remains difficult with several recent trials showing limited or no benefit. If treatment comes with only marginal improvements, concerns about adverse events become more relevant. We therefore examined the type and outcomes of side effects submitted to a public repository. METHODS: We searched the Federal Adverse Event Reporting System for reports associated with the treatment of dyspepsia or gastroparesis...
June 2, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28552340/long-term-follow-up-of-bilateral-subthalamic-deep-brain-stimulation-for-refractory-tardive-dystonia
#17
Zheng-Dao Deng, Dian-You Li, Chen-Cheng Zhang, Yi-Xin Pan, Jin Zhang, Haiyan Jin, Kristina Zeljec, Shi-Kun Zhan, Bo-Min Sun
BACKGROUND: No effective treatment for tardive dystonia (TD) has been well established. Deep brain stimulation (DBS) can ameliorate motor manifestations in primary dystonia, and may also be an effective approach for TD. OBJECTIVES: This study aimed to illuminate the long-term efficacy and safety of subthalamic nucleus (STN)-DBS in treating TD. METHODS: Ten patients with refractory TD underwent STN-DBS therapy and were assessed by the Burke-Fahn-Marsden dystonia rating scale (BFMDRS), Abnormal Involuntary Movement Scale (AIMS), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), and the Short Form (36) Health Survey (SF-36) at four time points: pre-operation, 1 week post-operation, 6 months post-operation, and at a final long-term postsurgical follow-up time point...
May 19, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28552054/neurotoxicity-of-insecticides
#18
Julien Cassereau, Marc Ferré, Arnaud Chevrollier, Philippe Codron, Christophe Verny, Chadi Homedan, Guy Lenaers, Vincent Procaccio, Pascale May-Panloup, Pascal Reynier
BACKGROUND: Human exposure to insecticides raises serious public health concerns worldwide. Insecticides constitute a wide-ranging heterogeneous group of chemicals, most of which target the nervous system and disrupt neurometabolism and/or neurotransmission. Although the acute effects of insecticide poisoning in humans are well documented, the chronic and long-term effects remain difficult to investigate. OBJECTIVES AND METHOD: We sought to review the present state-of-knowledge of acute, chronic, neurodevelopmental and neurological consequences of human exposure to insecticides...
May 26, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28539959/tardive-dystonia-related-with-aripiprazole
#19
Sunghwan Kim, Seung-Yup Lee, MinSeob Kim, Kyoung-Uk Lee
Tardive dystonia is characterized by sustained, generally slow involuntary twisting movements. It is estimated to occur at a frequency of 1% to 4% among patients who are taking an antipsychotic agent. Unlike the first generation antipsychotics, the second generation antipsychotics are less likely to cause neuroleptic-induced movement disorder. For aripiprazole, only a few cases have been reported for tardive dystonia. We present a young male, who developed a severe tardive dystonia after taking aripiprazole for 5 years...
May 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/28520698/valbenazine-ingrezza-for-tardive-dyskinesia
#20
(no author information available yet)
No abstract text is available yet for this article.
May 22, 2017: Medical Letter on Drugs and Therapeutics
keyword
keyword
112950
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"